|
CONCOMITANT USE MAY MAKE PATIENT MORE SENSITIVE TO MYOCARDIAL DEPRESSANT AND CONDUCTION EFFECTS OF HALOGENATED INHALATIONAL ANESTHETICS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED POTENTIAL FOR HEPATOTOXICITY
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
CONCURRENT ADMINISTRATION WITH ADRENALINE OR OTHER SYMPATHOMIMETICS MAY CAUSE VENTRICULAR FIBRILLATION
|
HALOTHANE DIMINISHES THE EFFECT OF ERGOTAMINE ON UTERUS
|
HALOTHANE DIMINISHES THE EFFECT OF ERGOTAMINE ON UTERUS
|
HALOTHANE DIMINISHES THE EFFECT OF ERGOTAMINE ON UTERUS
|
HALOTHANE DIMINISHES THE EFFECT OF ERGOTAMINE ON UTERUS
|
HALOTHANE DIMINISHES THE EFFECT OF ERGOTAMINE ON UTERUS
|
HALOTHANE DIMINISHES THE EFFECT OF ERGOTAMINE ON UTERUS
|
PROPOFOL DOSE IS REDUCED IF GIVEN WITH NITROUS OXIDE & HALOGENATED ANAESTHETICS
|
XANTHINES WHEN CONCOMITANTLY USED WITH HALOTHANE OR KETAMINE MAY HAVE INCREASED RISK OF SYNERGISTIC TOXICITY & MAY CAUSE CARDIAC ARRHYTHMIAS
|
INCREASED RISK OF PULMONARY TOXICITY
|
DOXAPRAM THERAPY SHOUL BE DELAYED FOR ATLEAST 10 MTS FOLLOWING DISCONTINUANCE OF ANAESTHESIA WITH HALOTHANE, CYCLOPROPANE,ENFLURANE WHICH ARE KNOWN TO SENSITIZE MYOCARDIUM TO CATECHOLAMINES,SINCE AN INCREASE IN EPINEPHRINE RELEASE HAS BEEN NOTED
|
HALOTHANE MAY REDUCE THE EFFECTTIVENESS OF PARASYMPATHOMIMETICS
|
HALOTHANE MAY REDUCE THE EFFECTTIVENESS OF PARASYMPATHOMIMETICS
|
HALOTHANE MAY REDUCE THE EFFECTTIVENESS OF PARASYMPATHOMIMETICS
|
HALOTHANE MAY REDUCE THE EFFECTTIVENESS OF PARASYMPATHOMIMETICS
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF POSTOPERATIVE RESPIRATORY DEPRESSION OR ENHANCE IT
|